GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
This article was originally published in PharmAsia News
Executive Summary
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.